Literature DB >> 21983195

Development of a liquid chromatography-tandem mass spectrometry assay of six antimicrobials in plasma for pharmacokinetic studies in premature infants.

Michael Cohen-Wolkowiez1, Nicole R White, Arlene Bridges, Daniel K Benjamin, Angela D M Kashuba.   

Abstract

This method provides a simple extraction procedure, as well as a validated, sensitive, and specific liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of ampicillin, piperacillin, tazobactam, meropenem, acyclovir, and metronidazole in human plasma. The method was validated over concentration ranges specific for each compound, with a lower limit of quantification of 50-300 ng/mL and a sample volume of 50 μL. The method is accurate and precise, with within- and between-day accuracy ranging from 85 to 110% and 92 to 110%, respectively, and within- and between-day precision of 89-111% and 91-109%, respectively. Simplicity, low plasma volume, and high throughput make this method suitable for clinical pharmacokinetic studies in premature infants. Copyright Â
© 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21983195      PMCID: PMC3210405          DOI: 10.1016/j.jchromb.2011.09.031

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  10 in total

1.  Bioanalytical method validation--a revisit with a decade of progress.

Authors:  V P Shah; K K Midha; J W Findlay; H M Hill; J D Hulse; I J McGilveray; G McKay; K J Miller; R N Patnaik; M L Powell; A Tonelli; C T Viswanathan; A Yacobi
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

2.  A high performance liquid chromatography system for the simultaneous assay of some antibiotics commonly found in combination in clinical samples.

Authors:  D E Holt; J de Louvois; R Hurley; D Harvey
Journal:  J Antimicrob Chemother       Date:  1990-07       Impact factor: 5.790

3.  Pharmacokinetic study of piperacillin in newborns relating to gestational and postnatal age.

Authors:  N Kacet; M Roussel-Delvallez; C Gremillet; J P Dubos; L Storme; P Lequien
Journal:  Pediatr Infect Dis J       Date:  1992-05       Impact factor: 2.129

4.  Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry.

Authors:  Byung Hwa Jung; Naser L Rezk; Arlene S Bridges; Amanda H Corbett; Angela D M Kashuba
Journal:  Biomed Chromatogr       Date:  2007-10       Impact factor: 1.902

5.  Microanalysis of beta-lactam antibiotics and vancomycin in plasma for pharmacokinetic studies in neonates.

Authors:  Maurice J Ahsman; Enno D Wildschut; Dick Tibboel; Ron A Mathot
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

6.  Very low birth weight preterm infants with early onset neonatal sepsis: the predominance of gram-negative infections continues in the National Institute of Child Health and Human Development Neonatal Research Network, 2002-2003.

Authors:  Barbara J Stoll; Nellie I Hansen; Rosemary D Higgins; Avroy A Fanaroff; Shahnaz Duara; Ronald Goldberg; Abbot Laptook; Michelle Walsh; William Oh; Ellen Hale
Journal:  Pediatr Infect Dis J       Date:  2005-07       Impact factor: 2.129

7.  Metronidazole population pharmacokinetics in preterm neonates using dried blood-spot sampling.

Authors:  Maysa Suyagh; Paul S Collier; Jeffrey S Millership; Godwill Iheagwaram; Muriel Millar; Henry L Halliday; James C McElnay
Journal:  Pediatrics       Date:  2011-01-10       Impact factor: 7.124

8.  Reported medication use in the neonatal intensive care unit: data from a large national data set.

Authors:  Reese H Clark; Barry T Bloom; Alan R Spitzer; Dale R Gerstmann
Journal:  Pediatrics       Date:  2006-06       Impact factor: 7.124

9.  Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network.

Authors:  Barbara J Stoll; Nellie Hansen; Avroy A Fanaroff; Linda L Wright; Waldemar A Carlo; Richard A Ehrenkranz; James A Lemons; Edward F Donovan; Ann R Stark; Jon E Tyson; William Oh; Charles R Bauer; Sheldon B Korones; Seetha Shankaran; Abbot R Laptook; David K Stevenson; Lu-Ann Papile; W Kenneth Poole
Journal:  Pediatrics       Date:  2002-08       Impact factor: 7.124

10.  Simultaneous determination of five beta-lactam antibiotics (cefepim, ceftazidim, cefuroxim, meropenem and piperacillin) in human plasma by high-performance liquid chromatography with ultraviolet detection.

Authors:  Raphaël Denooz; Corinne Charlier
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-02-02       Impact factor: 3.205

  10 in total
  10 in total

1.  Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design.

Authors:  Stéphanie Leroux; Mark A Turner; Chantal Barin-Le Guellec; Helen Hill; Johannes N van den Anker; Gregory L Kearns; Evelyne Jacqz-Aigrain; Wei Zhao
Journal:  Clin Pharmacokinet       Date:  2015-12       Impact factor: 6.447

Review 2.  Pharmacokinetic studies in infants using minimal-risk study designs.

Authors:  Julie Autmizguine; Daniel K Benjamin; P Brian Smith; Mario Sampson; Philippe Ovetchkine; Michael Cohen-Wolkowiez; Kevin M Watt
Journal:  Curr Clin Pharmacol       Date:  2014

3.  Quantification of Cefepime, Meropenem, Piperacillin, and Tazobactam in Human Plasma Using a Sensitive and Robust Liquid Chromatography-Tandem Mass Spectrometry Method, Part 1: Assay Development and Validation.

Authors:  Ronilda D'Cunha; Thanh Bach; Beth Ann Young; Peizhi Li; Demet Nalbant; Jun Zhang; Patricia Winokur; Guohua An
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

4.  Population pharmacokinetics of metronidazole evaluated using scavenged samples from preterm infants.

Authors:  Michael Cohen-Wolkowiez; Daniele Ouellet; P Brian Smith; Laura P James; Ashley Ross; Janice E Sullivan; Michele C Walsh; Arlene Zadell; Nancy Newman; Nicole R White; Angela D M Kashuba; Daniel K Benjamin
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

5.  Developing a SWATH capillary LC-MS/MS method for simultaneous therapeutic drug monitoring and untargeted metabolomics analysis of neonatal plasma.

Authors:  Jingcheng Xiao; Jian Shi; Ruiting Li; Lucy Her; Xinwen Wang; Jiapeng Li; Matthew J Sorensen; Varsha Bhatt-Mehta; Hao-Jie Zhu
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2021-07-27       Impact factor: 3.318

6.  Developmental pharmacokinetics of piperacillin and tazobactam using plasma and dried blood spots from infants.

Authors:  Michael Cohen-Wolkowiez; Kevin M Watt; Chenguang Zhou; Barry T Bloom; Brenda Poindexter; Lisa Castro; Jamie Gao; Edmund V Capparelli; Daniel K Benjamin; P Brian Smith
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.938

7.  Fast Determination of Ingredients in Solid Pharmaceuticals by Microwave-Enhanced In-Source Decay of Microwave Plasma Torch Mass Spectrometry.

Authors:  Rui Su; Xinchen Wang; Changming Hou; Meiling Yang; Keke Huang; Huanwen Chen
Journal:  J Am Soc Mass Spectrom       Date:  2017-06-19       Impact factor: 3.109

8.  Simultaneous Quantification of Nine Antimicrobials by LC-MS/MS for Therapeutic Drug Monitoring in Critically Ill Patients.

Authors:  Sophie Neugebauer; Christina Wichmann; Sibylle Bremer-Streck; Stefan Hagel; Michael Kiehntopf
Journal:  Ther Drug Monit       Date:  2019-02       Impact factor: 3.681

9.  Population pharmacokinetics of intravenous acyclovir in preterm and term infants.

Authors:  Mario R Sampson; Barry T Bloom; Robert W Lenfestey; Barrie Harper; Angela D Kashuba; Ravinder Anand; Daniel K Benjamin; Edmund Capparelli; Michael Cohen-Wolkowiez; P Brian Smith
Journal:  Pediatr Infect Dis J       Date:  2014-01       Impact factor: 3.806

Review 10.  Innovative Study Designs Optimizing Clinical Pharmacology Research in Infants and Children.

Authors:  Stephen J Balevic; Michael Cohen-Wolkowiez
Journal:  J Clin Pharmacol       Date:  2018-10       Impact factor: 2.860

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.